SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAPI, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 52.279
AS - Asia 25.775
EU - Europa 14.465
SA - Sud America 4.415
Continente sconosciuto - Info sul continente non disponibili 1.383
AF - Africa 643
OC - Oceania 201
Totale 99.161
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 50.800
SG - Singapore 9.273
CN - Cina 5.368
IT - Italia 3.986
BR - Brasile 3.342
VN - Vietnam 2.716
HK - Hong Kong 2.415
DE - Germania 1.897
UA - Ucraina 1.891
BD - Bangladesh 1.605
GB - Regno Unito 1.346
FI - Finlandia 1.325
TR - Turchia 1.187
FR - Francia 867
NL - Olanda 770
JP - Giappone 749
CA - Canada 713
RU - Federazione Russa 646
SE - Svezia 577
IN - India 574
ID - Indonesia 539
MX - Messico 420
AR - Argentina 382
PL - Polonia 315
IQ - Iraq 197
ZA - Sudafrica 185
AU - Australia 179
EC - Ecuador 166
ES - Italia 163
PK - Pakistan 162
CO - Colombia 153
AT - Austria 123
PH - Filippine 122
MY - Malesia 106
VE - Venezuela 102
SA - Arabia Saudita 95
MA - Marocco 94
PY - Paraguay 84
KR - Corea 83
BE - Belgio 79
UZ - Uzbekistan 76
EG - Egitto 72
LT - Lituania 72
AE - Emirati Arabi Uniti 69
CL - Cile 69
TW - Taiwan 68
TN - Tunisia 67
JM - Giamaica 63
KE - Kenya 63
CR - Costa Rica 55
PE - Perù 54
CZ - Repubblica Ceca 53
TH - Thailandia 45
CH - Svizzera 42
IE - Irlanda 42
DZ - Algeria 41
GT - Guatemala 38
UY - Uruguay 33
JO - Giordania 32
KZ - Kazakistan 31
NP - Nepal 31
PT - Portogallo 29
LB - Libano 28
HN - Honduras 27
RO - Romania 27
AL - Albania 26
IL - Israele 26
AZ - Azerbaigian 24
GR - Grecia 24
BO - Bolivia 23
TT - Trinidad e Tobago 22
IR - Iran 21
SV - El Salvador 21
NI - Nicaragua 20
NZ - Nuova Zelanda 20
ET - Etiopia 19
HR - Croazia 18
PS - Palestinian Territory 18
RS - Serbia 18
BG - Bulgaria 17
DO - Repubblica Dominicana 17
MK - Macedonia 15
PR - Porto Rico 15
BB - Barbados 14
EE - Estonia 14
PA - Panama 14
EU - Europa 13
GE - Georgia 13
HU - Ungheria 13
NG - Nigeria 12
BH - Bahrain 11
OM - Oman 11
SY - Repubblica araba siriana 11
DK - Danimarca 10
SN - Senegal 10
VI - Stati Uniti Isole Vergini 10
MD - Moldavia 9
SI - Slovenia 9
XK - ???statistics.table.value.countryCode.XK??? 9
BY - Bielorussia 8
Totale 97.578
Salva come PNG Salva come JPEG
Città #
Ashburn 5.977
Singapore 5.672
Fairfield 4.048
Woodbridge 3.632
San Jose 3.229
Houston 2.687
Hong Kong 2.367
Jacksonville 2.060
Santa Clara 1.998
Council Bluffs 1.819
Dallas 1.707
Chandler 1.631
Seattle 1.593
Wilmington 1.438
Beijing 1.399
Ann Arbor 1.327
Cambridge 1.319
Los Angeles 1.057
New York 1.037
Ho Chi Minh City 896
Helsinki 732
Izmir 702
Tokyo 701
Milan 640
Nanjing 639
Hanoi 634
Princeton 567
Lauterbourg 549
Munich 520
San Diego 384
Jakarta 375
Ferrara 349
Chicago 347
Boardman 318
São Paulo 286
Washington 285
Rome 278
Warsaw 278
Mexico City 257
Buffalo 253
Toronto 239
Orem 234
Shanghai 219
San Francisco 214
London 210
Denver 204
Nanchang 197
Atlanta 183
Tianjin 178
Montreal 176
Shenyang 173
Phoenix 167
Hefei 155
Brooklyn 144
Frankfurt am Main 143
Moscow 143
Addison 131
Da Nang 130
Hebei 124
Changsha 116
Lappeenranta 116
Dearborn 112
Naples 112
Boston 111
Nuremberg 109
Bologna 104
Rio de Janeiro 104
Haiphong 103
Jiaxing 102
Turku 93
Chennai 92
Dong Ket 90
Mountain View 87
The Dalles 85
Guangzhou 84
Stockholm 84
Falls Church 80
Baghdad 78
Falkenstein 76
Redwood City 74
Norwalk 72
Zhengzhou 70
Columbus 67
Belo Horizonte 66
Tashkent 66
Johannesburg 65
Manchester 65
Amsterdam 64
Brasília 64
Curitiba 62
Miami 62
Mumbai 62
Figino 61
Quito 61
Sydney 61
Turin 61
Vienna 61
Kuala Lumpur 58
Dhaka 57
Philadelphia 56
Totale 62.624
Salva come PNG Salva come JPEG
Nome #
Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion 1.408
Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study 1.332
Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review 843
Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program 684
Air pollution and COPD: GOLD 2023 committee report 603
Asthma death. Part 1: Clinical phenotypes, epidemiology and risk factors 549
Asthma 530
N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses 463
From Gold 0 to Pre-COPD 458
Value of fiberoptic bronchoscopy in addition to 18F-FDG-PET/CT in the differentiation of solitary pulmonary nodules: a prospective study 451
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial 412
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations 354
Role of Stem Cells in the Pathogenesis of COPD and Pulmonary Emphysema 353
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial 344
Polmonite da ipersensibilità da antigeni aviari in un italiano adulto 336
Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review 328
Targeting Th2 cells in asthmatic airways 311
Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A GOLD Science Committee 2022 Review 308
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial 304
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS) 294
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD 293
Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells 290
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial 289
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 285
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD 280
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 277
Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial 269
Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial 261
Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study 259
Primary pulmonary epithelioid hemangioendothelioma: A rare cause of PET-negative pulmonary nodules 256
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial 253
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal 251
Oxygen radical scavengers inhibit clastogenic activity induced by sonication of human serum 249
Emphysema contribution to the progression of chronic obstructive pulmonary disease. 248
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 248
COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma 245
Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma 243
A human rhinovirus model of chronic obstructive pulmonary disease exacerbations 240
Bronchopulmonary inflammation and airway smooth muscle hyperresponsiveness induced by nitrogen dioxide in guinea pigs 238
Severe Pneumonia following intravescical BCG therapy in a patient with bladder cancer. 233
Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma 232
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial 231
Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients 230
Alteration of adenosine receptore in patients with chronic obstructive pulmonary disease 229
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 228
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 228
A serum proteome signature to predict mortality in severe COVID-19 patients 228
Respiratory Syncytial Virus Infection in Older Adults: An Update 228
Reducing agents decrease the oxidative burst and improve clinical outcomes in COPD patients: A randomised controlled trial on the effects of sulphurous thermal water inhalation 226
Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial 225
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline 225
Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD 224
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 224
Malattie polmonari primitive da cause dismetaboliche. 222
Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma 222
Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease 222
A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease 221
Airway inflammatory profile is correlated with symptoms in stable COPD: A longitudinal proof-of-concept cohort study 221
Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies 221
Effect of subchronic in vivo exposure to nitrogen dioxide on lung tissue inflammation, airway microvascular leakage, and in vitro bronchial muscle responsiveness in rats 219
Activation of NF-kappaB transcription factor in asthma death 219
Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up 219
Diffuse pulmonary meningothelial like nodules simulating metastatic thymoma 219
Cellule staminali e patologia polmonare dell’adulto 217
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis 217
Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients 217
Asthma management 216
Natural Killer Cells in SARS-CoV-2-Vaccinated Subjects with Increased Effector Cytotoxic CD56dim Cells and Memory-Like CD57+NKG2C+CD56dim Cells 215
Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy 215
A randomized, double-blinded, double-dummy efficacy and safety study of budesonide-formoterol Spiromax® compared to budesonide-formoterol Turbuhaler® in adults and adolescents with persistent asthma 215
Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium 214
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients 213
COPD: early diagnosis and treatment to slow disease progression 212
A new combination therapy for asthma: bridging the gap between effectiveness in trials and clinical practice? 212
Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes 210
COPD exacerbations: definitions and classifications 209
Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. 209
Immune Response to Mycobacterium tuberculosis Infection in the Parietal Pleura of Patients with Tuberculous Pleurisy 209
Interleukin-13 and-4 expression in the central airways of smokers with chronic bronchitis 208
Enfisema polmonare: prospettive di terapia 207
A defective type 1 response to rhinovirus in atopic asthma 207
Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells 207
A Novel Insight into Adaptive Immunity in Chronic Obstructive Pulmonary Disease B Cell Activating Factor Belonging to the Tumor Necrosis Factor Family 207
Role of xanthine oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells 206
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations 205
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 204
Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study 203
Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD 203
A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler 202
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study 202
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer 201
Apporto esogeno di riducenti e attività del rinovirus HRV16 200
Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease 200
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics 199
Rhinovirus vaccination: the case against 199
Achieving the balance between evidence and simplicity 199
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary 199
Models of infection and exacerbations in COPD. 198
Rhinovirus Infection Induces Degradation of Antimicrobial Peptides and Secondary Bacterial Infection in Chronic Obstructive Pulmonary Disease 198
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma 198
Totale 28.687
Salva come PNG Salva come JPEG
Categoria #
all - tutte 447.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 19.972
Totale 467.268
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.475 0 0 320 258 197 236 283 293 204 380 461 1.843
2022/20234.213 575 103 145 491 619 645 179 385 531 65 314 161
2023/20242.742 248 267 113 83 137 279 78 136 88 259 348 706
2024/202511.287 303 293 998 331 1.307 813 351 716 1.934 1.653 1.447 1.141
2025/202638.479 2.708 1.677 3.921 4.392 4.676 2.199 4.067 2.238 3.792 4.235 2.590 1.984
2026/202710.604 3.029 4.406 3.169 0 0 0 0 0 0 0 0 0
Totale 99.161